Literature DB >> 26743016

Combination of 5-ALA and iMRI in re-resection of recurrent glioblastoma.

Johanna Quick-Weller1, Stephanie Lescher2, Marie-Therese Forster1, Jürgen Konczalla1, Volker Seifert1, Christian Senft1.   

Abstract

Background Tumour resection plays a role in the initial treatment but also in the setting of recurrent glioblastoma (rGBM). To achieve maximum resection, 5-aminolevulinic acid (5-ALA) and intraoperative MRI (iMRI) are used as surgical tools. Aiming at complete tumour re-resection, we started combining iMRI with 5-ALA to find out if this leads to better surgical results. Methods We performed tumour resections in seven patients with rGBM, combining 5-ALA (20 mg/kg bodyweight) with iMRI (0.15 T). Radiologically complete resections were intended in all seven patients. We assessed intraoperative fluorescence findings and compared these with intraoperative imaging. All patients had early postoperative MRI (3 T) to verify final iMRI scans and received adjuvant treatment according to interdisciplinary tumour board decision. Results Median patient age was 63 years. Median KPS score was 90, and median tumour volume was 8.2 cm(3). In six of seven patients (85%), 5-ALA induced fluorescence of tumour-tissue was detected intraoperatively. All tumours were good to visualise with iMRI and contrast media. One patient received additional resection of residual contrast enhancing tissue on intraoperative imaging, which did not show fluorescence. Radiologically complete resections according to early postoperative MRI were achieved in all patients. Median survival since second surgery was 7.6 months and overall survival since diagnosis was 27.8 months. Conclusions 5-ALA and iMRI are important surgical tools to maximise tumour resection also in rGBM. However, not all rGBMs exhibit fluorescence after 5-ALA administration. We propose the combined use of 5-ALA and iMRI in the surgery of rGBM.

Entities:  

Keywords:  5-Aminolevulinic acid; extent of tumour resection; intraoperative MRI; recurrent glioblastoma

Mesh:

Substances:

Year:  2016        PMID: 26743016     DOI: 10.3109/02688697.2015.1119242

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  5 in total

1.  Red-light excitation of protoporphyrin IX fluorescence for subsurface tumor detection.

Authors:  David W Roberts; Jonathan D Olson; Linton T Evans; Kolbein K Kolste; Stephen C Kanick; Xiaoyao Fan; Jaime J Bravo; Brian C Wilson; Frederic Leblond; Mikael Marois; Keith D Paulsen
Journal:  J Neurosurg       Date:  2017-08-04       Impact factor: 5.115

Review 2.  Oncologic Procedures Amenable to Fluorescence-guided Surgery.

Authors:  Kiranya E Tipirneni; Jason M Warram; Lindsay S Moore; Andrew C Prince; Esther de Boer; Aditi H Jani; Irene L Wapnir; Joseph C Liao; Michael Bouvet; Nicole K Behnke; Mary T Hawn; George A Poultsides; Alexander L Vahrmeijer; William R Carroll; Kurt R Zinn; Eben Rosenthal
Journal:  Ann Surg       Date:  2017-07       Impact factor: 12.969

Review 3.  Updates in IDH-Wildtype Glioblastoma.

Authors:  Mary Jane Lim-Fat; James R Perry; Jawad M Melhem; Jay Detsky
Journal:  Neurotherapeutics       Date:  2022-05-31       Impact factor: 6.088

Review 4.  Agents for fluorescence-guided glioma surgery: a systematic review of preclinical and clinical results.

Authors:  Joeky T Senders; Ivo S Muskens; Rosalie Schnoor; Aditya V Karhade; David J Cote; Timothy R Smith; Marike L D Broekman
Journal:  Acta Neurochir (Wien)       Date:  2016-11-22       Impact factor: 2.216

Review 5.  Targeting Glucose Metabolism of Cancer Cells with Dichloroacetate to Radiosensitize High-Grade Gliomas.

Authors:  Kristina M Cook; Han Shen; Kelly J McKelvey; Harriet E Gee; Eric Hau
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.